e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
Olivier Sitbon, Vincent Cottin, Matthieu Canuet, Pierre Clerson, Virginie Gressin, Loïc Perchenet, Laurent Bertoletti, Hélène Bouvaist, François Picard, Grégoire Prévot, Emmanuel Bergot, Gérald Simonneau
Source:
Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020
Journal Issue:
September
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Olivier Sitbon, Vincent Cottin, Matthieu Canuet, Pierre Clerson, Virginie Gressin, Loïc Perchenet, Laurent Bertoletti, Hélène Bouvaist, François Picard, Grégoire Prévot, Emmanuel Bergot, Gérald Simonneau. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008
Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension
Source: Eur Respir J 2007; 29: 469-475
Year: 2007
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension
Source: Eur Respir J 2015; 46: 405-413
Year: 2015
Switching to macitentan in pulmonary arterial hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Initial dual oral combination therapy in pulmonary arterial hypertension
Source: Eur Respir J 2016; 47:1727-1736
Year: 2016
Differential response to the addition of sildenafil to bosentan monotherapy between idiopathic and scleroderma-associated pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 547s
Year: 2006
Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study
Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Year: 2011
Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data.
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights
Source: Eur Respir J 2015; 46: 414-421
Year: 2015
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Source: Eur Respir J 2004; 24: 353-359
Year: 2004
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 563s
Year: 2003
Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 205s
Year: 2005
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment
Year: 2012
Hemodynamical effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension
Source: International Congress 2019 – Pulmonary hypertension: clinical
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept